Cytokinetics CFO sells shares for tax withholding

Cytokinetics EVP and CFO Sung Lee reported an open-market sale of 4,935 shares of Common Stock at $62.15 per share.

(High)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Cytokinetics EVP and CFO Sung Lee reported an open-market sale of 4,935 shares of Common Stock at $62.15 per share. According to the footnote, this was a company-compelled sell-to-cover transaction to satisfy tax withholding obligations from RSU vesting, rather than a discretionary sale. After the transaction, Lee directly holds 87,127 shares, indicating he retains a substantial equity position.

Insider Trade Summary

Net Seller: 4,935 shares

Net Sell 1 txn

Insider Lee Sung

Role EVP, Chief Financial Officer

Sold 4,935 shs ($307K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,935	$62.15	$307K

Holdings After Transaction: Common Stock — 87,127 shares (Direct)

Footnotes (1)

F1. Company compelled sell-to-cover transaction to satisfy tax withholding obligations attributable to RSU vesting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cytokinetics (CYTK) CFO Sung Lee report in this Form 4?

Sung Lee reported selling 4,935 Cytokinetics shares at $62.15 each. The transaction was disclosed as an open-market sale, but a footnote explains it was compelled by the company to cover tax withholding from RSU vesting.

Why did the Cytokinetics (CYTK) CFO sell 4,935 shares?

The 4,935-share sale was executed to cover tax withholding on RSU vesting. A footnote states the company compelled the sell-to-cover transaction, meaning it was driven by tax obligations rather than a discretionary decision to reduce ownership.

How many Cytokinetics (CYTK) shares does the CFO hold after the sale?

After the transaction, Sung Lee holds 87,127 shares of Cytokinetics common stock. These shares are reported as directly owned, showing that despite the tax-related sale, he maintains a meaningful ongoing equity stake in the company.

Was the Cytokinetics (CYTK) CFO’s sale an open-market transaction?

The filing lists the transaction as an open-market sale at $62.15 per share. However, the footnote clarifies the sale was compelled by the company solely to satisfy tax withholding obligations associated with restricted stock unit vesting.

Does the Cytokinetics (CYTK) CFO’s Form 4 indicate a change in ownership strategy?

The filing mainly reflects a tax-related sell-to-cover event. With 4,935 shares sold for withholding and 87,127 shares still directly held, the data shows a routine tax transaction rather than a broad shift in the CFO’s ownership position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/18/2026 - 05:46 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Sung

(Last)

(First)

(Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/17/2026		S⁽¹⁾		4,935	D	$62.15	87,127	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Company compelled sell-to-cover transaction to satisfy tax withholding obligations attributable to RSU vesting.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Lee	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR